PanScan is a multi-stage genome-wide association study (GWAS) of pancreatic cancer conducted within the framework of the NCI Cohort Consortium. DCEG investigators have conducted three GWAS phases, PanScan I, II and III, and a meta-analysis with the Pancreatic Cancer Case-Control Consortium (PanC4) GWAS that collectively have led to the discovery of 20 loci in the human genome where common variants associated with risk for pancreatic cancer. Additional epidemiologic and genomic studies using data from these initial studies are now underway.
The next phase of the project (PanScan IV) will analyze additional pancreatic cancer cases from multiple cohorts, case-control, population-based, and biobank studies—including those from PanScan I, II, and III—to discover novel regions of the genome associated with pancreatic cancer susceptibility. This work is being done in collaboration between the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium (PanC4) and pancreatic cancer studies worldwide.